Prof Michael Linden | VP Gene Therapy & Head, GMI

Prof Michael Linden, VP Gene Therapy & Head, GMI, Pfizer

Following a Ph.D. in Biochemistry and Molecular Biology from the University of Zürich Switzerland, Dr Linden held faculty positions at Mount Sinai School of Medicine in New York and King’s College London, engaged in the field of AAV biology and AAV-mediated gene therapy.  Most recently Michael joined Pfizer Inc as the Vice President of Gene Therapy to lead the Genetic Medicine Institute in London to help establish gene therapy.  


Day 1 Orphan 14th Nov @ 17:50

The future of gene therapies for rare disease: Managing the rapid progression of gene therapies

  • Review of industry trends and recent collaborative development programmes
  • What can we expect moving forward into 2018?

back to speakers